Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.38 |
| ▸ | PDE2A | O00408 | 4/20 | 0.38 |
| ▸ | CDK4 | P11802 | 6/20 | 0.35 |
| ▸ | CCND1 | P24385 | 6/20 | 0.35 |
| ▸ | TYMS | P04818 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12102104 | 0.68 | SPR (0.50) | PARP1 | |
| SCHEMBL5989848 | 0.68 | KDM4E (0.37) | PDE2A | |
| SCHEMBL4052191 | 0.68 | PARP1 (0.39) | PARP1SMN1; SMN2 | |
| SCHEMBL22061369 | 0.65 | PDE2A (0.38) | PARP1PDE2ACDK4CCND1 | |
| SCHEMBL12102103 | 0.64 | TNKS (0.42) | PARP1PDE2ACDK4CCND1 | |
| SCHEMBL19222021 | 0.63 | L3MBTL1 (0.40) | CDK4CCND1 | |
| SCHEMBL5863219 | 0.63 | PDE2A (0.39) | PARP1PDE2ACDK4CCND1TYMS | |
| SCHEMBL16057987 | 0.62 | ALDH1A1 (0.39) | — | |
| SCHEMBL16007189 | 0.62 | TYMP (0.31) | SMN1; SMN2 | |
| SCHEMBL28523500 | 0.62 | PARP1 (0.41) | PARP1CDK4CCND1TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030118-B2 | Pyrrolotriazinone compounds and their use to treat diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-04-18 | — | — | US | disclosed |
| US-20030232832-A1 | Nitrogen compounds such as N-(3-Aminopropyl)-N-(1-(3-benzyl-4 -oxo-3,4-dihydropyrrolo(2,1-f)(1,2,4)-triazine-2-yl)-propyl)-4 -methylbenzamide, trifluoroacetic acid salt, used as anticarcinogenic or antiproliferative agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232832-A1 | Nitrogen compounds such as N-(3-Aminopropyl)-N-(1-(3-benzyl-4 -oxo-3,4-dihydropyrrolo(2,1-f)(1,2,4)-triazine-2-yl)-propyl)-4 -methylbenzamide, trifluoroacetic acid salt, used as anticarcinogenic or antiproliferative agents | CCNB1, NUMA1, CCNA1 | PARP1 233/4885PDE2A 3898/4885CDK4 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.